newsfilter
← Latest News
PR Newswire·

FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints

Boston Scientific Corporation (NYSE: BSX) today announced positive results from the pivotal FRACTURE Investigational Device Exemption (IDE) trial...